166 related articles for article (PubMed ID: 17949778)
1. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma.
Abdul-Al HM; Makhlouf HR; Wang G; Goodman ZD
Hum Pathol; 2008 Feb; 39(2):209-12. PubMed ID: 17949778
[TBL] [Abstract][Full Text] [Related]
2. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
Anatelli F; Chuang ST; Yang XJ; Wang HL
Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 positivity in B and C hepatitis and hepatocellular carcinomas.
Yildiz L; Baris S; Aydin O; Kefeli M; Kandemir B
Hepatogastroenterology; 2008; 55(88):2207-10. PubMed ID: 19260506
[TBL] [Abstract][Full Text] [Related]
4. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?
Kara B; Doran F; Kara IO; Akkiz H; Sandikci M
Int J Clin Pract; 2008 Aug; 62(8):1206-11. PubMed ID: 18284441
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
10. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy.
Wang FH; Yip YC; Zhang M; Vong HT; Chan KI; Wai KC; Wen JM
J Clin Pathol; 2010 Jul; 63(7):599-603. PubMed ID: 20501450
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
Kandil DH; Cooper K
Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
[TBL] [Abstract][Full Text] [Related]
13. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma.
Sakamoto M; Mori T; Masugi Y; Effendi K; Rie I; Du W
Intervirology; 2008; 51 Suppl 1():42-5. PubMed ID: 18544947
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma.
Honsová E; Lodererová A; Franková S; Oliverius M; Trunecka P
Cas Lek Cesk; 2011; 150(1):37-40. PubMed ID: 21400962
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
16. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.
Baumhoer D; Tornillo L; Stadlmann S; Roncalli M; Diamantis EK; Terracciano LM
Am J Clin Pathol; 2008 Jun; 129(6):899-906. PubMed ID: 18480006
[TBL] [Abstract][Full Text] [Related]
17. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
18. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
19. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma.
Jakubovic BD; Jothy S
Exp Mol Pathol; 2007 Apr; 82(2):184-9. PubMed ID: 17258707
[No Abstract] [Full Text] [Related]
[Next] [New Search]